Akero Therapeutics, Inc. (0K4.F)
- GlobeNewswire
Akero Therapeutics Reports First Quarter 2022 Financial Results
Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This YearSOUTH SAN FRANCISCO, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter financial results for the period ending March 31, 2022. “Our dedicated team continues to advance our two Phase 2b clinical tria
- GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in the following investor conferences this month: BofA Securities 2022 Healthcare Conference: Fireside chat on Wednesday, May 11 at 8:40 a.m. PT. in Las Vegas, Nevada.H.C. Wainwright Annual Global Life Sciences C
- Simply Wall St.
We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
